Skip to main content

Dr. Michael Weiner, the Founder of the Brain Health Registry and Principal Investigator of the Alzheimer’s Disease Neuroimaging Initiative (ADNI) Study, delivers his plenary speech “ADNI: Two Decades of Impact and the Path Forward” at the 2024 Alzheimer’s Association International Conference (AAIC) showcasing ADNI’s important work over the past 20 years. ADNI is one of the world’s largest observational studies on Alzheimer’s disease, and it shares valuable data with researchers worldwide to help find new treatments. Excitingly, ADNI has helped develop the first FDA-approved treatment for Alzheimer’s. Dr. Weiner is an emeritus Professor of Radiology at the University of San Francisco, and former Director of the Center for Imaging of Neurodegenerative Diseases at the VA Medical Center in San Francisco. Dr. Weiner’s introduction is given by Dr. Paulo Caramelli, professor of neurology at the Federal University of Minas Gerais in Brazil and chair of iSTAART Advisory Council. AAIC is the world’s largest international conference on dementia research and in 2024 was held from July 28th to August 1st.